Case report explores anticoagulation management in a severe hemophilia A patient, highlighting risks and strategies for cardiovascular health.
Therapeutic innovations in the last decades have significantly improved the life expectancy of patients with hemophilia (PWH). As a result, the prevalence of age-related diseases, such as cardiovascular conditions requiring anticoagulation, has increased within this population.[1] In patients with severe hemophilia, anticoagulation must be approached with caution and requires multidisciplinary consensus, given the delicate balance between the hemorrhagic risk associated with anticoagulation and the antithrombotic protection conferred by factor VIII (FVIII) or factor IX (FIX) deficiency.[2]
No takes yet. Share an insight, caveat, or question.
Sattler et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: